Fedratinib (BioDeep_00000858559)
代谢物信息卡片
化学式: C27H36N6O3S (524.2569466)
中文名称: TG-101348
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4
InChI: InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EJ - Janus-associated kinase (jak) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:91408
- KEGGdrug: D10630
- PubChem: 16722836
- DrugBank: DB12500
- ChEMBL: CHEMBL1287853
- CAS: 936091-26-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ken Ogasawara, Rebecca N Wood-Horrall, Mark Thomas, Michael Thomas, Liangang Liu, Mary Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Cancer chemotherapy and pharmacology.
2021 12; 88(6):941-952. doi:
10.1007/s00280-021-04346-7. [PMID: 34477937] - Yumei Ren, Yongbin Yan, Lei Zhen, Caihong Cao, Quan Wang, Yingying Zhang, Shan Zhu. Zhike Pingchuan Granule suppresses interleukin (IL)-6 or the medium of M2 macrophages induced apoptosis in human bronchial epithelial cells.
Bioengineered.
2021 12; 12(1):7694-7703. doi:
10.1080/21655979.2021.1982309. [PMID: 34608825] - Ken Ogasawara, Jeanelle Kam, Mark Thomas, Liangang Liu, Mary Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Cancer chemotherapy and pharmacology.
2021 09; 88(3):369-377. doi:
10.1007/s00280-021-04292-4. [PMID: 34019108] - Ken Ogasawara, Christine Xu, Jian Yin, Borje Darpo, Leon Carayannopoulos, Hongqi Xue, Maria Palmisano, Gopal Krishna. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Clinical pharmacology in drug development.
2021 04; 10(4):366-375. doi:
10.1002/cpdd.850. [PMID: 32673446] - Bin Gao, Lijuan Wang, Na Zhang, Miaomiao Han, Yubo Zhang, Huancai Liu, Dongli Sun, Yifei Liu. Screening Novel Drug Candidates for Kidney Renal Clear Cell Carcinoma Treatment: A Study on Differentially Expressed Genes through the Connectivity Map Database.
Kidney & blood pressure research.
2021; 46(6):702-713. doi:
10.1159/000518437. [PMID: 34818247] - Ken Ogasawara, Christine Xu, Vanaja Kanamaluru, Nicholas Siebers, Sekhar Surapaneni, Laurence Ridoux, Maria Palmisano, Gopal Krishna. Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects.
Cancer chemotherapy and pharmacology.
2020 08; 86(2):307-314. doi:
10.1007/s00280-020-04121-0. [PMID: 32748109] - Ken Ogasawara, Patricia M LoRusso, Anthony J Olszanski, Olivier Rixe, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Cancer chemotherapy and pharmacology.
2020 07; 86(1):87-95. doi:
10.1007/s00280-020-04102-3. [PMID: 32537715] - Ken Ogasawara, William B Smith, Christine Xu, Jian Yin, Maria Palmisano, Gopal Krishna. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
Cancer chemotherapy and pharmacology.
2020 06; 85(6):1109-1117. doi:
10.1007/s00280-020-04084-2. [PMID: 32449142] - Dandan Wu, Xuexian O Yang. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2020 Jun; 53(3):368-370. doi:
10.1016/j.jmii.2020.03.005. [PMID: 32205092] - Ken Ogasawara, Bradley Vince, Christine Xu, Meng Zhang, Maria Palmisano, Gopal Krishna. A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects.
Cancer chemotherapy and pharmacology.
2020 05; 85(5):995-1001. doi:
10.1007/s00280-020-04074-4. [PMID: 32318809] - Ken Ogasawara, Christine Xu, Vanaja Kanamaluru, Maria Palmisano, Gopal Krishna. Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Cancer chemotherapy and pharmacology.
2020 05; 85(5):899-906. doi:
10.1007/s00280-020-04067-3. [PMID: 32248324] - Ken Ogasawara, Simon Zhou, Gopal Krishna, Maria Palmisano, Yan Li. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Cancer chemotherapy and pharmacology.
2019 10; 84(4):891-898. doi:
10.1007/s00280-019-03929-9. [PMID: 31444617] - Pang Tao, Zhao Jing, Gao Shou-Hong, Piao Shu-Juan, Jiao Jian-Peng, Lu Wen-Quan, Chen Wan-Sheng. Effects of leptin on norepinephrine in acute ischemic stroke.
Die Pharmazie.
2019 08; 74(8):477-480. doi:
10.1691/ph.2019.9379. [PMID: 31526440] - Meng Zhang, Christine Xu, Lei Ma, Elias Shamiyeh, Jianyun Yin, Lisa L von Moltke, William B Smith. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
Clinical pharmacology in drug development.
2015 07; 4(4):315-21. doi:
10.1002/cpdd.161. [PMID: 27136912] - Meng Zhang, Christine R Xu, Elias Shamiyeh, Feng Liu, Jian Y Yin, Lisa L von Moltke, William B Smith. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.
Journal of clinical pharmacology.
2014 Apr; 54(4):415-21. doi:
10.1002/jcph.218. [PMID: 24165976] - Animesh Pardanani, Jason R Gotlib, Catriona Jamieson, Jorge E Cortes, Moshe Talpaz, Richard M Stone, Michael H Silverman, D Gary Gilliland, Jolene Shorr, Ayalew Tefferi. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011 Mar; 29(7):789-96. doi:
10.1200/jco.2010.32.8021. [PMID: 21220608]